AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 45 using EVA spread proxy -7.1%; growth durability 94.5.
Valuation
Valuation institutional score is 80 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 42 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 9 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. valuation provide support, while fundamentals and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 7.4% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -0.46). Confidence: 76%.
Live forward EPS implies next-12-month EPS of ₹5.67. Applying the stock's normalized valuation corridor produces a fair range of ₹175.94 to ₹259.74, with base value near ₹208.09 (+17.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹5.67
Forward P/E
31.3x
Base Fair Value
₹208.09
Fair Range
₹175.94 - ₹259.74
Upside To Base
+17.1%
Estimate Source
Live forward EPS
Growth Estimate
+94.6%
5Y Average
37.19
Current
34.00
Overvalued
45.81
Undervalued
31.03
5Y Average
14.97
Current
13.43
Overvalued
17.98
Undervalued
12.32
5Y Average
1.40
Current
1.26
Overvalued
1.62
Undervalued
1.19
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Undervalued | -22% vs avg | +10.6% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 22.3x Undervalued | -48% vs avg | +16.6% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Fair | +14% vs avg | +0.8% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Undervalued | -18% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -13% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -11% vs avg | +31.7% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 37.5x Fair | -13% vs avg | +29.9% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +111% vs avg | +121.8% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹63 CrJun 2026Latest net profit
₹6.72 CrJun 2026Latest EPS
₹1.39Jun 2026Net margin
13.5%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 65.86 | 98.64 | 82.33 | 90.62 | 49.61 | 73.53 | 71.94 | 75.94 | 51.33 | 42.39 | 93.88 | 118.04 | 62.76 |
| Expenses + | 65.04 | 89.94 | 70.27 | 75.28 | 44.33 | 63.84 | 60.54 | 63.65 | 46.26 | 45.59 | 76.20 | 91.45 | 54.30 |
| Operating Profit | 0.82 | 8.70 | 12.06 | 15.34 | 5.28 | 9.69 | 11.40 | 12.29 | 5.07 | -3.20 | 17.68 | 26.59 | 8.46 |
| OPM % | 1.25% | 8.82% | 14.65% | 16.93% | 10.64% | 13.18% | 15.85% | 16.18% | 9.88% | -7.55% | 18.83% | 22.53% | 13.48% |
| Other Income + | 1.48 | 5.79 | 1.29 | 8.15 | 2.12 | 1.12 | 0.75 | 1.92 | 1.80 | 0.32 | 0.32 | 1.00 | 2.91 |
| Interest | 0.95 | 0.74 | 1.02 | 1.78 | 0.69 | 0.83 | 0.99 | 1.26 | 1.04 | 0.83 | 1.16 | 1.17 | 1.24 |
| Depreciation | 1.12 | 1.16 | 1.17 | 1.16 | 1.20 | 1.23 | 1.33 | 1.24 | 1.22 | 1.16 | 1.25 | 1.34 | 1.35 |
| Profit before tax | 0.23 | 12.59 | 11.16 | 20.55 | 5.51 | 8.75 | 9.83 | 11.71 | 4.61 | -4.87 | 15.59 | 25.08 | 8.78 |
| Tax % | 30.43% | 15.25% | 23.75% | 25.50% | 23.05% | 24.57% | 24.62% | 26.56% | 23.64% | -18.07% | 22.13% | 25.24% | 23.46% |
| Net Profit + | 0.15 | 10.66 | 8.51 | 15.31 | 4.25 | 6.60 | 7.41 | 8.60 | 3.52 | -3.99 | 12.13 | 18.74 | 6.72 |
| EPS in Rs | 0.03 | 2.21 | 1.77 | 3.18 | 0.88 | 1.37 | 1.54 | 1.78 | 0.73 | -0.83 | 2.51 | 3.88 | 1.39 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).